Tab Application Banner
  • Users Online: 729
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
 
CASE REPORT
Ahead of Print

Adenosine deaminase 2 deficiency with a novel variant of CECR1 gene mutation: Responding to tumor necrosis factor antagonist therapy


1 Department of Pediatric, Salmaniya Medical Center, Manama, Kingdom of Bahrain
2 Department of Radiology, King Hamad university Hospital, Kingdom of Bahrain
3 Genetic Unit, Salmaniya Medical Complex, Manama, Bahrain, Kingdom of Bahrain

Correspondence Address:
Zakiya Saleh Al Mosawi,
Pediatric Rheumatologist, Consultant, Department of Pediatric, Salmaniya Medical Center, PO Box: 12, Manama
Kingdom of Bahrain
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/injr.injr_36_19

Deficiency of Adenosine deaminase 2 (DADA2) syndrome is a chronic, systemic, and inflammatory disorder, characterized by early-onset recurrent strokes, fever, livedo reticularis, and immunodeficiency. We report the case of a 4-year-old child, a product of consanguineous marriage, who presented with three episodes of hemiparesis within 1 year. She also manifested skin discoloration in the form of livedo reticularis. Workup with magnetic resonance imaging (MRI) of the brain revealed acute infarction in the right aspect of the cerebral peduncle and chronic lacunars infarct in the right thalamus with diffusion restriction. Repeated MRI after 5 months revealed diffuse loss of brain volume. The blood workup showed high inflammatory markers and significantly low adenosine deaminase 2 (ADA2) level. After being on corticosteroid and anticoagulant treatments, she suffered from a recurrent episode of cerebral infarction, after which she was commenced on tumor necrosis factor (TNF)-antagonist therapy in addition to monthly fresh plasma infusion. Thereafter, there was no cerebral insult reported for >18 months. The genetic study of the child and her parents revealed a homozygous mutation c. 336C>A, p. (His112Gln) in the CECR1 gene, and her parents were heterozygous for the same variant. This variant was not previously reported in literature. We would suggest to link this novel variant c. 336C>A, p. (His112Gln) of CECR1 gene mutation with the clinical picture, along with the positive response to TNF-antagonist therapy in the era of ADA2 deficiency syndrome.


Print this article
Search
 Back
 
  Search Pubmed for
 
    -  Al Mosawi ZS
    -  Abduljawad HO
    -  Busehail MY
    -  Al Moosawi BM
 Citation Manager
 Article Access Statistics
 Reader Comments
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed89    
    PDF Downloaded2    

Recommend this journal